irinotecan has been researched along with tanespimycin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alan, H; Chou, TC; Schwartz, GK; Sheikh, TN; Tse, AN | 1 |
| Brown, K; Carvajal, R; Chung, K; Egorin, MJ; Gonen, M; Kelsen, D; Klimstra, DS; Lefkowitz, R; Maki, R; Manova-Todorova, K; Mui, J; O'Reilly, E; Schwartz, GK; Shah, M; Sheikh, T; Sikorski, R; Tipian, C; Tse, AN; Wu, N | 1 |
1 trial(s) available for irinotecan and tanespimycin
| Article | Year |
|---|---|
A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Camptothecin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HSP90 Heat-Shock Proteins; Humans; Irinotecan; Lactams, Macrocyclic; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2008 |
1 other study(ies) available for irinotecan and tanespimycin
| Article | Year |
|---|---|
90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
Topics: Apoptosis; Benzoquinones; Camptothecin; Cell Cycle; Cell Cycle Proteins; Cell Survival; Checkpoint Kinase 1; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Interactions; G2 Phase; Gene Expression Regulation, Neoplastic; HCT116 Cells; HSP90 Heat-Shock Proteins; Humans; Irinotecan; Lactams, Macrocyclic; Nuclear Proteins; Protein Kinases; Protein-Tyrosine Kinases; Time Factors; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2009 |